(4-Methylphenyl)-(10-phenothiazinyl)methanone, also known as **chlorpromazine**, is a **phenothiazine antipsychotic drug**. It's **not** just a research chemical; it's a widely used medication for the treatment of **schizophrenia** and other mental disorders. Here's why it's important:
* **Historical Significance:** Chlorpromazine was the first antipsychotic drug to be developed and introduced in 1952. It revolutionized the treatment of severe mental illnesses like schizophrenia.
* **Mechanism of Action:** Chlorpromazine acts as a **dopamine receptor antagonist**. This means it blocks the effects of dopamine, a neurotransmitter involved in mood, motivation, and movement. By reducing dopamine activity in the brain, chlorpromazine helps alleviate the symptoms of psychosis, such as hallucinations and delusions.
* **Clinical Uses:** Chlorpromazine is used to treat:
* **Schizophrenia:** It effectively reduces positive symptoms like hallucinations and delusions.
* **Mania:** It can be used to manage episodes of mania in bipolar disorder.
* **Severe anxiety:** Chlorpromazine can be used to reduce anxiety in patients with severe anxiety disorders.
* **Nausea and vomiting:** It can also be used to treat nausea and vomiting related to surgery, chemotherapy, or other medical conditions.
* **Research Interest:** Despite being widely used, there's still active research interest in chlorpromazine:
* **New Indications:** Research is ongoing to explore its potential use in other conditions, such as obsessive-compulsive disorder and Alzheimer's disease.
* **Mechanism of Action:** Studies aim to better understand how chlorpromazine interacts with specific brain receptors and pathways.
* **Drug Delivery:** Researchers are exploring new drug delivery methods for chlorpromazine to improve its effectiveness and reduce side effects.
While chlorpromazine is a valuable medication, it has potential side effects like drowsiness, dizziness, and weight gain. It's essential to discuss the risks and benefits with your healthcare provider before taking chlorpromazine or any other medication.
ID Source | ID |
---|---|
PubMed CID | 3473393 |
CHEMBL ID | 397100 |
CHEBI ID | 93656 |
Synonym |
---|
OPREA1_194230 |
CHEMBL397100 , |
smr001537727 |
MLS002608923 |
(10h-phenothiazin-10-yl)(p-tolyl)methanone |
cid_3473393 |
bdbm50219212 |
BRD-K94919853-001-01-9 |
(4-methylphenyl)-phenothiazin-10-ylmethanone |
CHEBI:93656 |
Q27165345 |
(4-methylphenyl)-(10-phenothiazinyl)methanone |
Class | Description |
---|---|
phenothiazines | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 0.0580 | 10.6949 | 26.6086 | AID602310 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
streptokinase A precursor | Streptococcus pyogenes M1 GAS | EC50 (µMol) | 46.5410 | 0.0600 | 8.9128 | 130.5170 | AID2137 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID300872 | Inhibition of human plasma BuChE activity | 2007 | Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19 | Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. |
AID300873 | Inhibition of recombinant human AChE activity | 2007 | Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19 | Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |